Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatectomy | 4 | 2025 | 56 | 1.640 |
Why?
|
| Pancreatic Neoplasms | 5 | 2025 | 509 | 1.280 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2020 | 2 | 0.860 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2021 | 1 | 0.780 |
Why?
|
| Gallbladder | 1 | 2021 | 8 | 0.780 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 467 | 0.730 |
Why?
|
| Gastrostomy | 1 | 2020 | 6 | 0.680 |
Why?
|
| Patient Readmission | 1 | 2021 | 103 | 0.670 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 29 | 0.670 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 35 | 0.660 |
Why?
|
| Patient Transfer | 1 | 2017 | 42 | 0.550 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 168 | 0.480 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 287 | 0.450 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2020 | 42 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2025 | 129 | 0.350 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2020 | 5 | 0.350 |
Why?
|
| Ampulla of Vater | 2 | 2020 | 6 | 0.350 |
Why?
|
| Pancreatic Fistula | 2 | 2021 | 14 | 0.340 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 164 | 0.300 |
Why?
|
| Humans | 14 | 2025 | 27145 | 0.290 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2025 | 110 | 0.270 |
Why?
|
| Prognosis | 4 | 2025 | 762 | 0.260 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 463 | 0.240 |
Why?
|
| Retrospective Studies | 5 | 2025 | 2465 | 0.230 |
Why?
|
| England | 1 | 2021 | 34 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 375 | 0.190 |
Why?
|
| Exosomes | 1 | 2023 | 86 | 0.180 |
Why?
|
| Aged | 6 | 2025 | 5223 | 0.180 |
Why?
|
| Duodenal Neoplasms | 1 | 2020 | 6 | 0.180 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 3 | 0.170 |
Why?
|
| Receptors, Somatostatin | 1 | 2020 | 8 | 0.170 |
Why?
|
| Trauma Centers | 2 | 2018 | 115 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 31 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 46 | 0.170 |
Why?
|
| Intestine, Small | 1 | 2020 | 66 | 0.170 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 119 | 0.170 |
Why?
|
| Deoxycytidine | 1 | 2020 | 63 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2020 | 97 | 0.170 |
Why?
|
| Choledochal Cyst | 1 | 2019 | 5 | 0.170 |
Why?
|
| Middle Aged | 6 | 2025 | 6907 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2019 | 19 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 98 | 0.160 |
Why?
|
| Patient Selection | 1 | 2020 | 143 | 0.160 |
Why?
|
| Hospital Costs | 1 | 2018 | 29 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2018 | 29 | 0.150 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 9 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2018 | 31 | 0.150 |
Why?
|
| Spinal Cord Injuries | 1 | 2018 | 55 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 130 | 0.150 |
Why?
|
| Risk Factors | 2 | 2021 | 2036 | 0.150 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 35 | 0.150 |
Why?
|
| Length of Stay | 1 | 2018 | 218 | 0.140 |
Why?
|
| Male | 7 | 2025 | 13017 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2021 | 606 | 0.130 |
Why?
|
| Female | 7 | 2025 | 14635 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 811 | 0.120 |
Why?
|
| Adult | 4 | 2025 | 7498 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 767 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2017 | 1223 | 0.110 |
Why?
|
| Survival Rate | 2 | 2025 | 412 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2025 | 594 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 217 | 0.080 |
Why?
|
| Sex Factors | 2 | 2019 | 451 | 0.070 |
Why?
|
| Leucovorin | 1 | 2025 | 16 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2025 | 53 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 69 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 1939 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 29 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 55 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 2286 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 64 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2020 | 9 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 9 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 104 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 96 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 54 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 180 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 189 | 0.040 |
Why?
|
| Gastroenterology | 1 | 2019 | 14 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 279 | 0.040 |
Why?
|
| Contrast Media | 1 | 2019 | 94 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 1269 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2018 | 33 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 37 | 0.040 |
Why?
|
| Linear Models | 1 | 2018 | 202 | 0.040 |
Why?
|
| Prevalence | 1 | 2019 | 475 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 234 | 0.040 |
Why?
|
| Oklahoma | 1 | 2018 | 976 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 2629 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 2991 | 0.020 |
Why?
|